Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection
- PMID: 3366841
- DOI: 10.1016/s0378-4347(00)81078-6
Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection
Abstract
The reversed-phase high-performance liquid chromatography with electrochemical detection was used to quantify plasma and urine levels of vinblastine, vincristine, vindesine and a metabolite of vinblastine, desacetylvinblastine. Sample clean-up consisted of solid-phase extraction with a Bond Elut CN column. The extracts were separated on a Hypersil ODS column. The mobile phase consisted of a mixture of methanol and 10 mM phosphate buffer (pH 7.0). The limit of sensitivity using electrochemical detection was 100 pg on-column for all compounds with a signal-to-noise ratio of 3. Quantification of the compounds in human plasma and urine was possible down to 1 ng/ml (ca. 1 pmol). Pharmacokinetic results show that the sensitivity of the method is adequate for drug monitoring in clinical research.
Similar articles
-
Solid-phase extraction of vinblastine and vincristine from plasma and urine: variable drug recoveries due to non-reproducible column packings.J Chromatogr. 1987 Feb 20;414(1):91-100. doi: 10.1016/0378-4347(87)80027-0. J Chromatogr. 1987. PMID: 3571394
-
High-performance liquid chromatographic determination of vinca-alkaloids in plasma and urine.J Chromatogr. 1985 Dec 13;345(2):309-21. doi: 10.1016/0378-4347(85)80168-7. J Chromatogr. 1985. PMID: 4086600
-
Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.Cancer Chemother Pharmacol. 1997;39(4):286-90. doi: 10.1007/s002800050574. Cancer Chemother Pharmacol. 1997. PMID: 9025768
-
Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.Pharm World Sci. 1994 Jun 10;16(3):164-6. doi: 10.1007/BF01877488. Pharm World Sci. 1994. PMID: 7920369 Review. No abstract available.
-
Pharmacokinetics and metabolism of vinca alkaloids.Cancer Surv. 1993;17:269-81. Cancer Surv. 1993. PMID: 8137344 Review.
Cited by
-
Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma.Cancer Chemother Pharmacol. 2021 Apr;87(4):501-511. doi: 10.1007/s00280-020-04220-y. Epub 2021 Jan 8. Cancer Chemother Pharmacol. 2021. PMID: 33416909
-
Phase I study of 21 days continuous infusion with vindesine.Br J Cancer. 1989 Mar;59(3):471-2. doi: 10.1038/bjc.1989.97. Br J Cancer. 1989. PMID: 2930717 Free PMC article. No abstract available.
-
Preclinical and clinical pharmacology of vinca alkaloids.Drugs. 1992;44 Suppl 4:1-16; discussion 66-9. doi: 10.2165/00003495-199200444-00002. Drugs. 1992. PMID: 1283846 Review.
-
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.
-
The current and future place of vinorelbine in cancer therapy.Drugs. 1992;44 Suppl 4:36-45; discussion 66-9. doi: 10.2165/00003495-199200444-00005. Drugs. 1992. PMID: 1283849 Review.